Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term.

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol Myers Squibb (NYSE:BMY) on Thursday noticed a decline in its stock price. This after saying it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to ...

A clinical trial comparing a one-page medication handout proposed by the U.S. Food and Drug Administration (FDA) with an ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

For more than a decade, the Food and Drug Administration (FDA) has made diversity in clinical trials a focus, including by issuing guidance, ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...

AttoSure, a premier drug and alcohol testing laboratory serving workplaces and healthcare institutions across the UK, proudly announces its recent achievements in securing certification to ISO 27001 ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basis Fourth quarter diluted earnings per share were $1.20; adjusted1 ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...